Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joel R Eisner

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Fertility and Sterility|January 10, 2002
Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excessJoel R Eisner, Melissa A Barnett, Daniel A Dumesic, et al.
Obesity Research|February 13, 2003
Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestationJoel R Eisner, Daniel A Dumesic, Joseph W Kemnitz, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2014
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitorsStephen W Rafferty, Joel R Eisner, William R Moore, et al.
The Journal of Clinical Endocrinology and Metabolism|December 8, 2004
Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeysCristin M Bruns, Scott T Baum, Ricki J Colman, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2019
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancerCody J Peer, Keith T Schmidt, Jessica D Kindrick, et al.
Hormones & Cancer|January 18, 2018
Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast CancerJessica L Christenson, Jane B Trepel, Haythem Y Ali, et al.
Breast Cancer Research and Treatment|September 30, 2018
Male breast cancer: a disease distinct from female breast cancerAyca Gucalp, Tiffany A Traina, Joel R Eisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerShilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Breast Cancer Research and Treatment|May 11, 2018
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancerAditya Bardia, Ayca Gucalp, Noashir DaCosta, et al.
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Fertility and Sterility|January 10, 2002
Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excessJoel R Eisner, Melissa A Barnett, Daniel A Dumesic, et al.
Obesity Research|February 13, 2003
Increased adiposity in female rhesus monkeys exposed to androgen excess during early gestationJoel R Eisner, Daniel A Dumesic, Joseph W Kemnitz, et al.
Bioorganic & Medicinal Chemistry Letters|April 30, 2014
Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitorsStephen W Rafferty, Joel R Eisner, William R Moore, et al.
The Journal of Clinical Endocrinology and Metabolism|December 8, 2004
Insulin resistance and impaired insulin secretion in prenatally androgenized male rhesus monkeysCristin M Bruns, Scott T Baum, Ricki J Colman, et al.
Cancer Chemotherapy and Pharmacology|August 2, 2019
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancerCody J Peer, Keith T Schmidt, Jessica D Kindrick, et al.
Hormones & Cancer|January 18, 2018
Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast CancerJessica L Christenson, Jane B Trepel, Haythem Y Ali, et al.
Breast Cancer Research and Treatment|September 30, 2018
Male breast cancer: a disease distinct from female breast cancerAyca Gucalp, Tiffany A Traina, Joel R Eisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2018
Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate CancerShilpa Gupta, Luke T Nordquist, Mark T Fleming, et al.
Breast Cancer Research and Treatment|May 11, 2018
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancerAditya Bardia, Ayca Gucalp, Noashir DaCosta, et al.
British Journal of Cancer|May 26, 2022
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancerAnna R Michmerhuizen, Lynn M Lerner, Connor Ward, et al.
Pageof 2